Wegovy, the brand-name GLP-1 receptor agonist, carries a list price exceeding $1,300 monthly, yet most commercial insurance plans classify it as a weight loss drug rather than a metabolic treatment and refuse to cover it
In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise
Clinical evidence documents: Reduced fasting blood glucose and improved insulin sensitivity Reduction in visceral fat linked to cardiovascular disease Improvements in blood pressure for patients with hypertension at baseline In men, reduced body fat improves testosterone-to-estrogen balance, since fat tissue converts testosterone to estrogen via aromatase In women, reduced visceral fat supports more stable hormonal signaling, especially relevant during perimenopause and menopause How Tirzepatide Differs from Traditional Weight Loss Traditional diets force a calorie deficit through willpower
Finally, the majority of trial participants were White women
The Role of Bacteriostatic Water Bacteriostatic water (BW) is the preferred diluent for peptide reconstitution
"Most importantly, GLP-1 medications should be viewed as part of a comprehensive treatment plannot a standalone solution," she said
